4.7 Review

Tumor stroma as targets for cancer therapy

Journal

PHARMACOLOGY & THERAPEUTICS
Volume 137, Issue 2, Pages 200-215

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2012.10.003

Keywords

Tumor microenvironment; Cancer-associated fibroblasts; Extracellular matrix; Cancer signaling; Cancer therapy

Funding

  1. ovarian cancer Specialized Programs of Research Excellence (SPORE) [IP50CA83638]
  2. National Institutes of Health and Ovarian Cancer Research Fund
  3. National Institutes of Health through MD Anderson's Cancer Center Support [CA016672]
  4. National Natural Science Foundation of China (NSFC) [81070582]
  5. [R01CA131183-01A2]

Ask authors/readers for more resources

Cancer is not only composed malignant epithelial component but also stromal components such as fibroblasts, endothelial cells, and inflammatory cells, by which an appropriate tumor microenvironment (TME) is formed to promote tumorigenesis, progression, and metastasis. As the most abundant component in the TME, cancer-associated fibroblasts (CAFs) are involved in multifaceted mechanistic details including remodeling the extracellular matrix, suppressing immune responses, and secreting growth factors and cytokines that mediate signaling pathways to extensively affect tumor cell growth and invasiveness, differentiation, angiogenesis, and chronic inflammatory milieu. Today, more and more therapeutic strategies are purposefully designed to target the TME as well as tumor cells. This review will focus on the role of CAFs in tumor development and the novel strategies to target this component to inhibit the tumor growth. (C) 2012 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available